| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,245,681 ) |
| | 2025 | 2025 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PL STE 6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA281020 | Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer) | 000 | 8 | NIH | 6/25/2025 | $1,245,681 |
| | 2025 | 2023 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PL STE 6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44DE023725 | Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | 000 | 6 | NIH | 6/6/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $3,096,329 ) |
| | 2024 | 2024 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PL STE 6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA272095 | Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings | 001 | 3 | NIH | 4/3/2024 | $1,012,303 |
| | 2024 | 2024 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PL STE 6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA281020 | Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer) | 000 | 7 | NIH | 6/14/2024 | $2,084,026 |
| | 2024 | 2022 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PL STE 6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA272095 | Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings | 000 | 1 | NIH | 4/1/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,971,956 ) |
| | 2023 | 2023 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44DE023725 | Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | 000 | 6 | NIH | 1/5/2023 | $984,664 |
| | 2023 | 2023 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA272095 | Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings | 000 | 2 | NIH | 3/27/2023 | $987,292 |
| | 2023 | 2021 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R01FD006325 | Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017 | 000 | 3 | FDA | 11/14/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,180,112 ) |
| | 2022 | 2022 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44DE023725 | Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | 000 | 5 | NIH | 1/10/2022 | $779,005 |
| | 2022 | 2022 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA272095 | Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings | 000 | 1 | NIH | 2/24/2022 | $399,482 |
| | 2022 | 2022 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA272095 | Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings | 001 | 1 | NIH | 7/14/2022 | $1,625 |
|
| Issue Date FY: 2021 ( Subtotal = $1,282,698 ) |
| | 2021 | 2021 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44DE023725 | Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | 000 | 4 | NIH | 2/3/2021 | $1,183,038 |
| | 2021 | 2021 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R01FD006325 | Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017 | 000 | 3 | FDA | 6/30/2021 | $99,660 |
| | 2021 | 2020 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 000 | 6 | NIH | 8/26/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,498,847 ) |
| | 2020 | 2020 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 000 | 6 | NIH | 6/22/2020 | $999,657 |
| | 2020 | 2020 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R01FD006325 | Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017 | 000 | 2 | FDA | 6/25/2020 | $398,400 |
| | 2020 | 2020 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R01FD006325 | Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017 | 000 | 2 | FDA | 6/25/2020 | $100,000 |
| | 2020 | 2020 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 001 | 6 | NIH | 8/21/2020 | $790 |
| | 2020 | 2017 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44DE023725 | Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | 000 | 3 | NIH | 1/10/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,635,472 ) |
| | 2019 | 2019 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 002 | 5 | NIH | 7/19/2019 | $4,318 |
| | 2019 | 2019 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 001 | 5 | NIH | 6/24/2019 | $1,083,847 |
| | 2019 | 2019 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R01FD006325 | Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017 | 000 | 1 | FDA | 9/5/2019 | $449,307 |
| | 2019 | 2019 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 000 | 4 | NIH | 1/11/2019 | $98,000 |
|
| Issue Date FY: 2018 ( Subtotal = $999,072 ) |
| | 2018 | 2018 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 001 | 4 | NIH | 7/17/2018 | $999,072 |
| | 2018 | 2017 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 000 | 3 | NIH | 5/1/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $2,170,339 ) |
| | 2017 | 2017 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 001 | 3 | NIH | 2/1/2017 | $1,170,342 |
| | 2017 | 2017 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44DE023725 | Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | 000 | 3 | NIH | 2/17/2017 | $999,997 |
| | 2017 | 2015 | PRIVO TECHNOLOGIES, INC. | 200 CORPORATE PLACESUITE6B | PEABODY | MA | 01960-3840 | ESSEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 000 | 1 | NIH | 1/31/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $2,225,704 ) |
| | 2016 | 2016 | PRIVO TECHNOLOGIES, LLC | 13 BRISTOL STREET, UNIT 1 | CAMBRIDGE | MA | 02141 | MIDDLESEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 001 | 2 | NIH | 2/12/2016 | $54,577 |
| | 2016 | 2016 | PRIVO TECHNOLOGIES, LLC | 13 BRISTOL STREET, UNIT 1 | CAMBRIDGE | MA | 02141 | MIDDLESEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 002 | 2 | NIH | 7/22/2016 | $197,341 |
| | 2016 | 2016 | PRIVO TECHNOLOGIES, LLC | 13 BRISTOL STREET, UNIT 1 | CAMBRIDGE | MA | 02141 | MIDDLESEX | USA | R44DE023725 | Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | 001 | 2 | NIH | 8/17/2016 | $265,000 |
| | 2016 | 2016 | PRIVO TECHNOLOGIES, LLC | 13 BRISTOL STREET, UNIT 1 | CAMBRIDGE | MA | 02141 | MIDDLESEX | USA | R44DE023725 | Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | 000 | 2 | NIH | 2/24/2016 | $999,997 |
| | 2016 | 2016 | PRIVO TECHNOLOGIES, LLC | 13 BRISTOL STREET, UNIT 1 | CAMBRIDGE | MA | 02141 | MIDDLESEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 000 | 2 | NIH | 1/13/2016 | $708,789 |
|
| Issue Date FY: 2015 ( Subtotal = $293,491 ) |
| | 2015 | 2015 | PRIVO TECHNOLOGIES, LLC | 13 BRISTOL STREET, UNIT 1 | CAMBRIDGE | MA | 02141 | MIDDLESEX | USA | R44CA192875 | Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | 000 | 1 | NIH | 6/12/2015 | $293,491 |
|
| Issue Date FY: 2014 ( Subtotal = $220,675 ) |
| | 2014 | 2014 | PRIVO TECHNOLOGIES, LLC | 13 BRISTOL STREET, UNIT 1 | CAMBRIDGE | MA | 02141 | MIDDLESEX | USA | R43DE023725 | Customized nanotechnology based treatment of Oral Cancer | 000 | 1 | NIH | 8/29/2014 | $220,675 |
|
|
